FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine

Abstract:

The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I–III) vaccine trials against canine visceral leishmaniasis (92–95% of protection and 76–80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune® vaccine for canine prophylaxis in Brazil. The immune response raised by the vaccine is long lasting, immunotherapeutic and reduces dog infectivity blocking the transmission of the disease, as revealed by an in vivo assay. The preliminary epidemiological control data of vaccinated areas in Brazil indicate that, in spite of the still low vaccine coverage, there was a significant decrease in the incidence of the human and canine disease. A 36-kDa glycoprotein, in the FML complex, is the human marker of the disease, which was protective in mice as native recombinant protein or DNA vaccine. The …

Año de publicación:

2008

Keywords:

Fuente:

google